To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 24, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Hepatocellular Carcinoma
Interventions
BIOLOGICAL

EU307 CAR-T Cell

"* Dose to be administered: a single dose~* IV administration~* Dosing rate: To be administrated at a rate of approximately 2 mL/min"

Trial Locations (4)

Unknown

RECRUITING

National Cancer Center, Gyeonggi-do

RECRUITING

Severance Hospital, Seoul

RECRUITING

SoonChunHyang University Hospital Seoul, Seoul

RECRUITING

The Catholic University of Korea Seoul ST.MARY'S Hospital., Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Eutilex

INDUSTRY